Frontlight ResearchEarly access
Liver and biliary tract cancer trials in Spain
45 of 56 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 2Not yet taking people in SpainA Phase 2 Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 14 worldwide
- Run by
- Elevar Therapeutics Inc.
See details and how to join2025-523923-22-00 - Phase 1/2Taking peopleA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 616 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07020221 - Phase 2Taking peopleVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Zaragoza
- Age
- 18 years to 100 years
- People
- 104 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00 - Phase 2Taking peopleA Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Elevar Therapeutics
See details and how to joinNCT07359820 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1/2Taking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Barcelona, Madrid, Oviedo
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - Phase 2Not yet taking people in SpainDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 3Taking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Barcelona, Córdoba, Madrid, Málaga, Pamplona, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Barcelona, Madrid, Pamplona
- Age
- 18 years and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - Phase 1Taking peopleA First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
- Where
- L'Hospitalet de Llobregat, Madrid, Pamplona
- Age
- 18 years and over
- People
- 148 worldwide
- Run by
- Bayer
See details and how to joinNCT06764316 · EU 2024-516615-25-00 - Phase 2Not yet taking people in SpainEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - Phase 1/2Taking peopleA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Barcelona, Logroño, Madrid, Pozuelo de Alarcón
- Age
- 18 years and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona, Zaragoza
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1/2Not yet taking people in SpainFirst in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Where
- Barcelona, Pamplona
- Age
- 18 years and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06795022 · EU 2024-516698-56-00 - Phase 3Taking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Barcelona, Madrid, Málaga, Santander
- Age
- 18 years to 99 years
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - Phase 3Taking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Barcelona, Madrid, Pamplona, Santander
- Age
- 18 years and over
- People
- 1,220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - Phase 1/2Not yet taking people in SpainSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Barcelona, Madrid, Oviedo
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - Phase 1Taking peopleA Study of ZW251 in Participants With Advanced Solid Tumors
- Where
- Barcelona, Logroño, Madrid, Málaga, Pamplona
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Zymeworks BC Inc.
See details and how to joinNCT07164313 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Barcelona, Madrid, Rioja, Valencia
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 2Taking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00